Text Size

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs (TOSCA)

This study is currently recruiting participants.
Verified May 2013 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01387594
First received: June 30, 2011
Last updated: May 15, 2013
Last verified: May 2013
History of Changes
  Purpose

Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.


Condition Intervention Phase
Crohn's Disease
Ileitis
Ileo-colonic and Colonic Crohn's Disease
Granulomatous Colitis
Regional Enteritis
Ulcerative Colitis
 Procedure: lumbar puncture
Drug: lumbar puncture
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Multi Center, Phase 1, Open Label Evaluation Of The Effect Of PF-00547659 (Anti Madcam Monoclonal Antibody) On Cerebrospinal Fluid (CSF) Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Are Anti- TNF Inadequate Responders (TOSCA)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Percent change from baseline (pre treatment) in absolute lymphocyte count in CSF in subjects with CD or UC after receiving 3 monthly doses of PF-00547659 [ Time Frame: Week 9-11 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Frequency of on treatment adverse events, withdrawal due to adverse events, and serious adverse events (SAEs) will be reported [ Time Frame: Week 36 ] [ Designated as safety issue: Yes ]
  • Proportion of subjects developing anti-drug antibodies (ADA) to PF-00547659 [ Time Frame: Week 36 ] [ Designated as safety issue: Yes ]
  • Frequency of injection site reactions and other hypersensitivity reactions [ Time Frame: Week 36 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: May 2012
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Interventions prior to treatment. Control arm
 Procedure: lumbar puncture
2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
Experimental: Cohort 2
Interventions prior to and after 3 monthly injections
 Drug: lumbar puncture
1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • males and females >=18 and =<75 years
  • For CD subjects: hsCRP > 5 mg/L and Harvey-Bradshaw Index > 8 OR when HBI cannot be determined (ie if stoma is present) or hsCRP < 5mg/L then: active lesions on colonoscopy or flexible sigmoidoscopy or active Crohn's disease on CT or MR enterography
  • For UC subjects: diagnosis of UC > 3 months; must have endoscopy to confirm active disease during screening; total mayo score of 6 to 12 points and moderate to severe disease on endoscopy

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • TB or active enteric infections
  • Entero vesicular fistulae
  • Prior use of natalizumab or vedolizumab
  • Right or left heart failure including symptomatic diastolic dysfunction or unexplained elevation of troponin I (>0.05 ng/mL)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01387594

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

Locations
Austria
Pfizer Investigational Site Recruiting
Wien, Austria, 1090
Belgium
Pfizer Investigational Site Recruiting
Brussels, Belgium, B-1070
Pfizer Investigational Site Recruiting
Leuven, Belgium, 3000
France
Pfizer Investigational Site Not yet recruiting
Lille Cedex, France, 59037
Germany
Pfizer Investigational Site Recruiting
Berlin, Germany, 13353
Pfizer Investigational Site Not yet recruiting
Kiel, Germany, 24105
Netherlands
Pfizer Investigational Site Recruiting
Amsterdam, Netherlands, 1105 AZ
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01387594     History of Changes
Other Study ID Numbers: A7281008
Study First Received: June 30, 2011
Last Updated: May 15, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Crohn's disease lumbar puncture anti-MAdCAM monoclonal antibody PF-00547659 Ulcerative Colitis

Additional relevant MeSH terms:
Ileal Diseases
Colitis
Colitis, Ulcerative
Crohn Disease
Enteritis
Ileitis
Ulcer
Gastroenteritis
Gastrointestinal Diseases
 Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013